Panacos Pharmaceuticals, Inc. PANC

Company Overview

Panacos Pharmaceuticals, Inc. (formerly traded on NASDAQ under the ticker PANC) was a U.S.-based biopharmaceutical company focused on the discovery and development of antiviral therapies, primarily targeting human immunodeficiency virus (HIV). The company operated within the biotechnology and pharmaceutical industries and concentrated on small-molecule therapeutics intended to address drug-resistant strains of HIV. Its principal value proposition centered on developing compounds with novel mechanisms of action that could complement or improve existing antiretroviral treatment regimens.

The company’s lead development efforts were concentrated around HIV maturation inhibitors, including the investigational drug bevirimat, which attracted industry attention as one of the first compounds in that therapeutic class. Panacos evolved from an early-stage biotechnology research organization into a clinical-stage antiviral developer during the 2000s. Public filings and historical market records indicate that the company later experienced financial and operational challenges, including reductions in workforce and restructuring activity. Data regarding continued standalone operations after its restructuring period is inconclusive based on available public sources.